The system utilizes advanced optical sensing technology to track glucose concentrations in tissue fluid, targeting adults managing diabetes. A key differentiator for the device is its longevity; the optical sensor and overtape are designed to remain in place for up to 28 days, reducing the frequency of routine replacements compared to many current market offerings. The detector and charger components are built for repeated use, aiming to streamline the daily management process for patients.

Michael Tillmann, Chairman and CEO of FiberSense, described the certification as a defining moment for the company. With regulatory approval in hand, the organization is pivoting its resources toward logistics, market access, and the final stages of manufacturing preparation. The company has already confirmed initial orders and anticipates the first deliveries to reach patients before the end of the year.

This glucose monitor serves as the first regulated application of FiberSense’s broader continuous multi-analyte platform. The firm is currently evaluating further sensor targets, including lactate, ketones, and cortisol. FiberSense, which traces its lineage to the Novartis-affiliated spin-off EyeSense, intends to expand this platform into a comprehensive biomarker sensing suite as clinical and regulatory evidence for additional analytes is established.